Multicenter study of method-dependent epidemiological cutoff values for detection of resistance in candida spp. and aspergillus spp. to amphotericin B and echinocandins for the etest agar diffusion method

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Espinel Ingroff, A ^a   Arendrup, M ^b   Canton, E ^c   Cordob, S ^a,d   Dannaoui, E ^e   Garcia Rodriguez, J ^f   Gonzalez, G M ^g   Govender, N P ^h   Martin Mazuelos, E ⁱ   Lackner, M ^a   Lass Florl, C ^j   Linares Sicilia, M J ^k   Rodriguez Iglesias, M A ^l   Pelaez, T ^m   Shields, R K ⁿ   Garcia Effron, G ^o   Guinea, J ^p   Sanguinetti, M ^q   Turnidger, J ^r  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b STATENS SERUM INSTITUT   (Denmark)

^c INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^d INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^h NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

ⁱ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k Universidad de Cordoba   (Spain)

^l HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^m HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁿ UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^o UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^p HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^q CATHOLIC UNIVERSITY   (Italy)

^r UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

Amphotericin B resistance; Antifungal resistance; Echinocandin resistance; ECVs; Etest ECVs; Etest MICs Aspergillus; Etest MICs Candida; Non WT; Susceptibility marker; WT isolates

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARGENTINA; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; EPIDEMIOLOGICAL CUTOFF VALUE; EPSILOMETER TEST; EUROPE; FUNGUS ISOLATION; FUNGUS MUTANT; GENE MUTATION; HUMAN; MEXICO; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; REFERENCE VALUE; SOUTH AFRICA; UNITED STATES; CLINICAL TRIAL; DISK DIFFUSION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MULTICENTER STUDY; SOUTH AND CENTRAL AMERICA;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; EUROPE; LATIN AMERICA; SOUTH AFRICA; UNITED STATES;

EID: 85009275081     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01792-16     Document Type: Article

References (47)

1. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Cast-agnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. ESCMID guidelines for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19-37. https://doi.org/10.1111/1469-0691.12039.
2. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papani-colaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50:1091-1100. https://doi.org/10.1086/651263.
3. Maschmeyer G, Haas A, Cornely OA. 2007. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67:1567-1601. https://doi.org/10.2165/00003495-200767110-00004.
4. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47: 1176-1184. https://doi.org/10.1086/592255.
5. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:1-50. https://doi.org/10.1093/cid/civ747.
6. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360. https://doi.org/10.1086/525258.
7. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts-Fourth informational supplement M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzales G, Guarro J, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Ostrosky-Zeichner L, Pelaez T, St-Germain G, Turnidge J. 2014. Mul-ticenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 58:916. https://doi.org/10.1128/AAC.02020-13.
10. Clinical and Laboratory Standards Institute. 2016. Epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M59 docu-ment. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Espinel-Ingroff A, Turnidge J. 2016. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Rev Iberoam Micol 33:63-75. https://doi.org/10.1016/j.riam.2016.04.001.
12. Arendrup MC, Meletiadis J, Mouton JW, Guinea J, Cuenca-Estrella M, Lagrou K, Howard SJ, Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Suscepti-bility Testing. 2016. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Infect Dis 22:571.e1-571.e4.
13. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing. 2014. EUCAST technical note on Can-dida and micafungin, anidulafungin and fluconazole. Mycoses 57: 377-379.
14. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Approved standard M38-A2. Clinical and Laboratory Standards Insti-tute, Wayne, PA.
15. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, Fuller J, Ghannoum M, Johnson E, Pelaez T, Pfaller M, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Asper-gillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 55:5150-5154. https://doi.org/10.1128/AAC.00686-11.
16. Lass-Flörl C, Arendrup MC, Rodriguez-Tudela JL, Cuenca-Estrella M, Don-nelly P, Hope W. 2011. EUCAST technical note on amphotericin B. Clin Microbiol Infect 17:E27-E29. https://doi.org/10.1111/j.1469-0691.2011.03644.x.
17. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. 2013. Break-points for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 16:81-95. https://doi.org/10.1016Zj.drup.2014.01.001.
18. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. https://doi.org/10.1111/j.1469-0691.2006.01377.x.
19. Shields RK, Nguyen MH, Press EG, Clancy CJ. 2014. Abdominal candidi-asis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 58:7601-7605. https://doi.org/10.1128/AAC.04134-14.
20. Alexander B, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724-1732. https://doi.org/10.1093/cid/cit136.
21. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller JF, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SRBS, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 57:5836-5842. https://doi.org/10.1128/AAC.01519-13.
22. Eschenauer G, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SH, Potoski BA, Clarke LG, Shields RK, Clancy CJ. 2014. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 58:1897-1906. https://doi.org/10.1128/AAC.02163-13.
23. Espinel-Ingroff A, Alvarez-Fernandez M, Cantón E, Carver PL, Chen SC-A, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Grancini A, Hanson KE, Kidd SE, Klinker K, Kubin CJ, Kus JV, Lockhart SR, Meletiadis J, Morris AJ, Pelaez T, Quindós G, Rodriguez-Iglesias M, Sánchez-Reus F, Shoham S, Wengenack NL, Borrell Solé N, Echeverria J, Esperalba J, Gómez de la Pedrosa GE, García García I, Linares MJ, Marco F, Merino P, Pemán J, Pérez Del Molino L, Roselló Mayans E, Rubio Calvo C, Ruiz Pérez de Pipaon M, Yagüe G, Garcia-Effron G, Guinea J, Perlin DS, Sanguinetti M, Shields R, Turnidge J. 2015. A multi-center study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafun-gin, caspofungin and micafungin using the Sensititre Yeast One colorimetric method. Antimicrob Agents Chemother 59:6725-6732. https://doi.org/10.1128/AAC.01250-15.
24. Biomérieux SA. 2013. Etest antifungal susceptibility testing package insert. bioMérieux SA, Chemin, France.
25. Biomérieux SA. 2013. Etest performance, interpretive criteria and quality control ranges table. bioMérieux SA, Chemin, France.
26. Shields RK, Nguyen MH, Press EG, Updike C, Clancy CJ. 2013. Caspofun-gin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 57:3528-3535. https://doi.org/10.1128/AAC.00136-13.
27. Arendrup MC, Garcia-Effron G, Lass-Florl C, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSIM27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and Iso-Sensitest media. Antimicrob Agents Chemother 54:426-439. https://doi.org/10.1128/AAC.01256-09.
28. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimi-crob Agents Chemother 52:4181-4183. https://doi.org/10.1128/AAC.00802-08.
29. Forastiero A, Garcia-Gil O, Garcia-Rubio R, Monteiro MC, Alastruey-Izquierdo Jordan J. 2015. Rapid development of Candida krusei echino-candin resistance during caspofungin therapy. Antimicrob Agents Chemother 59:6975-6982. https://doi.org/10.1128/AAC.01005-15.
30. Guinea J, Zaragoza Ó Escribano P, Martín-Mazuelos E, Pemán J, Sánchez-Reus F, Cuenca-Estrella M, Project CANDIPOP, GEIH-GEMICOMED (SEIMC), REIPI. 2014. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 58: 1529-1537. https://doi.org/10.1128/AAC.02155-13.
31. Marcos-Zambrano LJ, Escribano P, Sánchez C, Muñoz P, Bouza E, Guinea J. 2014. Antifungal resistance to fluconazole and echinocandins is not emerging in yeasts isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 58:4565-4572. https://doi.org/10.1128/AAC.02670-14.
32. Bordallo M, Escribano P, Gómez G, de la Pedrosa E, Laura Judith Marcos-Zambrano LJ, Cantón R, Emilio Bouza Guinea J. 2016. In vitro exposure to micafungin promotes echinocandins resistance in Candida glabrata clinical isolates, poster 1603. Abstr 26th Eur Cong Clin Microbiol Infect Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
33. Posteraro B, Spanu T, Fiori B, De Maio F, De Carolis E, Giaquinto A, Prete V, De Angelis G, Torelli R, D'Inzeo T, Vella A, De Luca A, Tumbarello M, Ricciardi W, Sanguinetti M. 2015. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre Yeast One: a nine-year experience at a large Italian teaching hospital. Antimicrob Agents Chemother 59:3944-3955. https://doi.org/10.1128/AAC.00285-15.
34. Espinel-Ingroff A. 2001. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 39:1360-1367. https://doi.org/10.1128/JCM.39.4.1360-1367.2001.
35. Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. 2001. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 39:4387-4389. https://doi.org/10.1128/JCM.39.12.4387-4389.2001.
36. Espinel-Ingroff A, Canton E, Peman J, Martín-Mazuelo E. 2010. Comparison of anidulafungin MICs determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. Antimicrob Agents Chemother 54: 1347-1350. https://doi.org/10.1128/AAC.01324-09.
37. Espinel-Ingroff A, Canton E, Pelaez T, Peman J. 2011. Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. Diagn Microbiol Infect Dis 70:54-59. https://doi.org/10.1016/j.diagmicrobio.2010.12.010.
38. Arendrup MC, Pfaller MA, The Danish Fungaemia Study Group. 2012. Caspofungin Etest susceptibility testing of Candida species: risk of mis-classification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother 56:3965-3968. https://doi.org/10.1128/AAC.00355-12.
39. Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti MA, Girmenia C. 2012. In vitro activities of amphotericin B and ambisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. J Antimicrob Agents 39:440-443. https://doi.org/10.1016/j.ijantimicag.2012.01.013.
40. Lamoth F, Alexander BD. 2015. Comparing Etestand broth microdilution for antifungal susceptibility testing of the most-relevant pathogenic molds. J Clin Microbiol 53:3176-3181. https://doi.org/10.1128/JCM.00925-15.
41. Bougnoux ME, Dannaoui E, Accoceberry I, Angoulvant A, Bailly E, Botterel F, Chevrier S, Chouaki T, Cornet M, Dalle F, Datry A, Dupuis A, Fekkar A, Gangneux J, Guitard J, Hennequin SC, Le Govic Y, Le Pape P, Maubon D, Ranque S, Sautour M, Sendid B, Chandeniertime J. 2016. Multicenter comparison of the Etest and EUCAST methods for antifungal susceptibility testing of Candida isolates to micafungin. Antimicrob Agents Chemother 60:5088-5091. https://doi.org/10.1128/AAC.00630-16.
42. Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 55: 2855-2859. https://doi.org/10.1128/AAC.01730-10.
43. Siopi M, Tsala M, Siafakas N, Zerva L, Meletiadis J. 2015. Evaluation of the "dip effect" phenomenon in antifungal susceptibility testing of Candida spp. against echinocandins by use ofgradient concentration strips. J Clin Microbiol 53:3654-3659. https://doi.org/10.1128/JCM.02073-15.
44. Pfaller MA, Diekema DJ, Jones RN, Castanheira M. 2014. Use of anidula-fungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4, 290 clinical isolates of Candida by using CLSI methods and interpretive criteria. J Clin Microbiol 52:3223-3229. https://doi.org/10.1128/JCM.00782-14.
45. Wanger A, Mills K, Nelson PW, Rex JH. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilu-tion method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 39:2550-2522.
46. Howell S, Hazen K, Brandt M. 2015. Candida, Cryptococcus, and other yeasts of medical importance, p 1984-2014. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of clinical microbiology, 11th ed. ASM Press, Washington, DC.
47. Chen S, Sorrell T, Meyer W. 2015. Aspergillus and Penicillium, p 2030-2056. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of clinical microbiology, 11th ed. ASM Press, Washington, DC.